Related Experiment Video
Updated: May 4, 2026
15:17
Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing
Published on: September 25, 2011
13.4K
DropArray™, a wall-less 96-well plate for uptake and immunofluorescence microscopy, confirms CD22 recycles
Gladys S Ingle1, Suzie J Scales
1Department of Molecular Biology, Genentech, 1 DNA Way, South San Francisco, CA, 94080, USA.
Traffic (Copenhagen, Denmark)
|December 17, 2013
Summary
Anti-CD22 antibodies rapidly internalize and recycle in B-cells, with minimal lysosomal degradation. This trafficking insight is crucial for optimizing antibody-drug conjugates in B-cell cancer therapies.
Area of Science:
- Immunology
- Cell Biology
- Oncology
Background:
- CD22 is a B-cell surface glycoprotein targeted by antibody-based cancer therapies.
- Understanding anti-CD22 antibody trafficking is vital for optimizing antibody-drug conjugate efficacy.
- Previous studies lacked clarity on whether anti-CD22 antibodies recycle or degrade, and if trafficking varies by antibody or cell type.
Purpose of the Study:
- To investigate the time-course and pathways of anti-CD22 antibody trafficking in various B-cell lines.
- To determine if anti-CD22 antibody trafficking is consistent across different antibodies and B-cell cancer types.
- To utilize novel DropArray™ technology for efficient simultaneous staining of suspension and adherent cells.
Main Methods:
- Employed DropArray™ technology for rapid, simultaneous staining of multiple cell samples.
- Examined the trafficking of five distinct anti-CD22 antibodies.
- Analyzed trafficking in eight B-cell lines representing four B-cell cancer types using dual immunofluorescence microscopy over time.
Main Results:
- All tested anti-CD22 antibodies rapidly internalized within 5 minutes in all B-cell lines.
- The primary trafficking pathway observed was recycling, with minimal lysosomal degradation.
- CD22 was found to localize to recycling endosomes even without antibody binding.
Conclusions:
- Anti-CD22 antibodies predominantly recycle in B-cells, contradicting prior assumptions of significant lysosomal degradation.
- Antibody trafficking appears consistent across different anti-CD22 antibodies and B-cell cancer types.
- These findings provide a basis for understanding differential efficacies of anti-CD22 antibody conjugates with varying payloads.
